These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23829877)

  • 21. Behavioral and neurophysiological effects of transdermal rotigotine in atypical parkinsonism.
    Moretti DV; Binetti G; Zanetti O; Frisoni GB
    Front Neurol; 2014; 5():85. PubMed ID: 24926284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idiopathic Parkinson's Disease at the End of Life: A Retrospective Evaluation of Symptom Prevalence, Pharmacological Symptom Management and Transdermal Rotigotine Dosing.
    Hindmarsh J; Hindmarsh S; Lee M
    Clin Drug Investig; 2021 Aug; 41(8):675-683. PubMed ID: 34213758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pramipexole-induced antecollis in patients with Parkinson's disease: Two cases and literature review.
    Iijima M; Osawa M; Uchiyama S; Kitagawa K
    eNeurologicalSci; 2015 Jun; 1():21-23. PubMed ID: 29468202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dropped Head Syndrome: The Importance of Neurophysiology in Distinguishing Myasthenia Gravis from Parkinson's Disease.
    Mangiardi M; Magliozzi A; Colosimo C; Marsili L
    Biomedicines; 2024 Aug; 12(8):. PubMed ID: 39200297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
    Baldwin CM; Keating GM
    CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spotlight on rotigotine in Parkinson's disease.
    Baldwin CM; Keating GM
    Drugs Aging; 2008; 25(2):175-7. PubMed ID: 18257604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
    Chung SJ; Asgharnejad M; Bauer L; Benitez A; Boroojerdi B; Heidbrede T; Little A; Kim HJ
    Expert Rev Neurother; 2017 Jul; 17(7):737-749. PubMed ID: 28548894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
    Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B;
    Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease.
    Schnitzler A; Leffers KW; Häck HJ
    Parkinsonism Relat Disord; 2010 Sep; 16(8):513-6. PubMed ID: 20605106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study.
    Moretti DV; Binetti G; Zanetti O; Frisoni GB
    Neuropharmacology; 2014 Oct; 85():284-9. PubMed ID: 24915072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson's Disease.
    Kataoka H; Sawada Y; Namizaki T; Shimozato N; Yoshiji H; Ueno S
    Front Neurol; 2017; 8():547. PubMed ID: 29085331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
    Naidu Y; Chaudhuri KR
    Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine.
    Braun M; Cawello W; Boekens H; Horstmann R
    Br J Clin Pharmacol; 2009 Feb; 67(2):209-15. PubMed ID: 19094160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
    Bogan RK
    Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversible antecollis associated with pramipexole in a patient with Parkinson's disease.
    Kim HJ; Jeon BS; Kim SH; Han SH
    J Clin Neurosci; 2012 Jun; 19(6):903-4. PubMed ID: 22353251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rotigotine for the treatment of Parkinson's disease.
    Morgan JC; Sethi KD
    Expert Rev Neurother; 2006 Sep; 6(9):1275-82. PubMed ID: 17009915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
    Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
    Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.